| Literature DB >> 26968702 |
Ye-Tao Wang1, Ya-Wen Gou1, Wen-Wen Jin1, Mei Xiao1, Hua-Ying Fang2.
Abstract
BACKGROUND: Studies examining the association between alcohol intake and the risk of pancreatic cancer have given inconsistent results. The purpose of this study was to summarize and examine the evidence regarding the association between alcohol intake and pancreatic cancer risk based on results from prospective cohort studies.Entities:
Keywords: Alcohol; Meta-analysis; Pancreatic cancer
Mesh:
Substances:
Year: 2016 PMID: 26968702 PMCID: PMC4788838 DOI: 10.1186/s12885-016-2241-1
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Flow diagram of the literature search andstudies selection process
Baseline characteristic of studies included
| Study | Country | Sex | Study design | Sample size | Cases | Age at baseline | Effect estimate | Follow-up (year) | Covariates in fully adjusted model | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| JACC [ | Japan | Men | Cohort | 46,465 | 94 | 40–79 | RR | 8.1 | Age andsmoking status | 7 |
| Women | Cohort | 64,327 | 97 | 40–79 | RR | 8.1 | ||||
| KIRS and MIHDPs [ | Lithuania | Men | Cohort | 7,132 | 77 | 45–59 | HR | 30.0 | Age, smoking status, education, BMI. | 8 |
| LWLH [ | US | Both | Cohort | 13,979 | 65 | 75.0 | RR | 9.0 | Sex, age andsmoking status | 6 |
| ATBC [ | Finland | Men | Cohort | 27,101 | 157 | 50–69 | HR | 13.0 | Age and intervention | 9 |
| NLCS [ | Netherland | Men | Cohort | 58,279 | 144 | 55–69 | HR | 13.3 | Age, sex, smoking status, EI, BMI, vegetable intake, and fruit intake | 9 |
| Women | Cohort | 62,573 | 115 | 55–69 | HR | 13.3 | ||||
| NIH-AARP [ | US | Men | Cohort | 280,084 | 748 | 50–71 | RR | 7.3 | Sex, smoking status, EI, energy-adjusted saturated fat, red meat, and total folate intake, BMI, PA, and DM | 7 |
| Women | Cohort | 190,597 | 401 | 50–71 | RR | 7.3 | ||||
| IWHS [ | US | Women | Cohort | 33,976 | 66 | 55–69 | RR | 8.0 | Age, smoking status | 6 |
| HPFS [ | US | Men | Cohort | 51,529 | 130 | 40–75 | RR | 12.0 | Age, smoking status, BMI, history of DM, history of cholecysectomy, and EI | 8 |
| NHS [ | US | Women | Cohort | 121,700 | 158 | 30–55 | RR | 16.0 | Age, smoking status, BMI, history of DM, history of cholecysectomy, and EI | 8 |
| CPS II [ | US | Men | Cohort | 453,770 | 3443 | >30 | RR | 24.0 | Age, sex, race/ethnicity, education, marital status, BMI, FHPC, and history of gallstones, DM, or smoking status | 9 |
| Women | Cohort | 576,697 | 3404 | >30 | RR | 24.0 | ||||
| TGP [ | Japan | Men | Cohort | 14,241 | 33 | >35 | HR | 7.0 | Age, smoking, BMI, history of DM | 7 |
| Women | Cohort | 16,585 | 18 | >35 | HR | 7.0 | ||||
| EPIC [ | Europe | Both | Cohort | 478,400 | 555 | 52.2 | RR | 8.9 | Age, sex, centre, smoking status, height and weight, and history of DM | 8 |
| MWS [ | UK | Women | Cohort | 1,290,000 | 1338 | 55.9 | RR | 7.2 | Age, region, socioeconomic status, smoking status, BMI and height | 7 |
| NYSC [ | US | Men | Cohort | 30,363 | 90 | >15 | RR | 7.0 | Smoking status, DM, BMI, and EI | 8 |
| Women | Cohort | 22,550 | 48 | >15 | RR | 7.0 | ||||
| BCDDP [ | US | Women | Cohort | 43,162 | 102 | 40–93 | RR | 11.0 | Smoking status, DM, BMI, and EI | 8 |
| CTS [ | US | Women | Cohort | 100,030 | 116 | >22 | RR | 8.1 | Smoking status, DM, BMI, and EI | 6 |
| CNBSS [ | Canada | Women | Cohort | 49,654 | 105 | 40–59 | RR | 16.5 | Smoking status, DM, BMI, and EI | 7 |
| PLCO [ | US | Men | Cohort | 29,914 | 90 | 55–74 | RR | 6.0 | Smoking status, DM, BMI, and EI | 6 |
| Women | Cohort | 28,315 | 60 | 55–74 | RR | 6.0 | ||||
| SMC [ | Swedish | Women | Cohort | 36,630 | 54 | 49–83 | RR | 6.8 | Smoking status, DM, BMI, and EI | 8 |
| COSM [ | Swedish | Men | Cohort | 45,338 | 75 | 45–79 | RR | 6.8 | Smoking status, DM, BMI, and EI | 8 |
| MCCS [ | Australia | Men | Cohort | 14,908 | 28 | 40–69 | RR | 15.0 | Smoking status, DM, BMI, and EI | 9 |
| Women | Cohort | 22,830 | 35 | 40–69 | RR | 15.0 |
*BMI body mass index, DM diabetes mellitus, EI energy intake, PA physical activity, FHPC family history of pancreatic cancer
Fig. 2Summary of the relative risks for the association between alcohol intake and the risk of pancreatic cancer
Fig. 3Relative risk estimates of pancreatic cancer for different type of alcohol intake
Fig. 4Dose–response analysis for curvilinear association between alcohol intake and relative risks of pancreatic cancer
Subgroup analysis of pancreatic cancer foralcohol intake versus the lowest intake
| Subroup | Light alcohol intake | Moderate alcohol intake | Heavy alcohol intake | Total alcohol intake | |
|---|---|---|---|---|---|
| Country | |||||
| Men | US | 0.92 (0.69–1.21) | 0.92 (0.77–1.11) | 1.22 (0.95–1.56) | 1.02 (0.83–1.25) |
| Europe | 1.09 (0.88–1.36) | 0.95 (0.62–1.46) | 1.21 (0.84–1.76) | 1.08 (0.90–1.30) | |
| Other | 0.64 (0.25–1.64) | 1.06 (0.64–1.76) | 0.89 (0.61–1.30) | 0.91 (0.68–1.22) | |
| Women | US | 1.00 (0.87–1.14) | 1.04 (0.79–1.35) | 1.27 (0.98–1.65) | 1.05 (0.94–1.16) |
| Europe | 0.91 (0.50–1.64) | 0.93 (0.75–1.15) | 1.17 (0.70–1.97) | 1.00 (0.82–1.23) | |
| Other | 0.83 (0.60–1.13) | 0.88 (0.56–1.38) | 1.23 (0.66–2.29) | 0.89 (0.70–1.13) | |
| Total cohort | US | 0.97 (0.88–1.08) | 1.00 (0.93–1.08) | 1.22 (1.14–1.30)* | 1.06 (0.98–1.14) |
| Europe | 0.99 (0.85–1.15) | 0.89 (0.80–1.00) | 1.08 (0.91–1.27) | 0.99 (0.90–1.10) | |
| Other | 0.81 (0.60–1.09) | 0.95 (0.67–1.34) | 0.97 (0.70–1.34) | 0.90 (0.75–1.08) | |
| Duration of follow-up (years) | |||||
| Men | 10 or more | 1.01 (0.87–1.17) | 0.89 (0.67–1.19) | 1.07 (0.80–1.42) | 1.00 (0.83–1.20) |
| <10 | 0.92 (0.56–1.51) | 0.96 (0.79–1.17) | 1.30 (1.11–1.52)* | 1.06 (0.89–1.27) | |
| Women | 10 or more | 0.96 (0.83–1.11) | 0.93 (0.67–1.29) | 1.40 (1.01–1.94)* | 1.01 (0.89–1.14) |
| <10 | 0.98 (0.82–1.18) | 1.01 (0.81–1.27) | 1.04 (0.93–1.16) | 0.99 (0.92–1.06) | |
| Total cohort | 10 or more | 0.99 (0.89–1.09) | 0.99 (0.91–1.08) | 1.20 (1.07–1.34)* | 1.02 (0.92–1.12) |
| <10 | 0.93 (0.81–1.06) | 0.93 (0.85–1.03) | 1.12 (0.99–1.26) | 1.01 (0.93–1.10) | |
| Adjusted smoking status | |||||
| Men | Yes | 0.98 (0.81–1.18) | 0.94 (0.80–1.11) | 1.19 (1.00–1.42) | 1.04 (0.90–1.19) |
| No | 1.02 (0.73–1.43) | 0.82 (0.49–1.37) | 0.99 (0.59–1.67) | 0.96 (0.75–1.23) | |
| Women | Yes | 0.97 (0.87–1.09) | 0.93 (0.83–1.04) | 1.07 (0.96–1.19) | 0.99 (0.93–1.06) |
| No | - | - | - | - | |
| Total cohort | Yes | 0.96 (0.89–1.05) | 0.98 (0.92–1.04) | 1.16 (1.06–1.26)* | 1.02 (0.95–1.08) |
| No | 1.02 (0.73–1.43) | 0.82 (0.49–1.37) | 0.99 (0.59–1.67) | 0.96 (0.75–1.23) | |
| Adjusted BMI | |||||
| Men | Yes | 0.98 (0.81–1.18) | 0.93 (0.79–1.10) | 1.19 (0.98–1.46) | 1.03 (0.88–1.20) |
| No | 1.02 (0.73–1.43) | 0.96 (0.66–1.40) | 1.01 (0.70–1.47) | 1.00 (0.81–1.23) | |
| Women | Yes | 0.94 (0.83–1.06) | 0.90 (0.80–1.01) | 1.07 (0.96–1.19) | 0.97 (0.91–1.04) |
| No | 1.18 (0.88–1.59) | 1.42 (0.74–2.73) | 1.20 (0.54–2.68) | 1.25 (0.99–1.58) | |
| Total cohort | Yes | 0.96 (0.87–1.05) | 0.98 (0.93–1.04) | 1.17 (1.06–1.30)* | 1.02 (0.95–1.09) |
| No | 1.00 (0.83–1.21) | 1.02 (0.80–1.31) | 1.00 (0.77–1.28) | 1.01 (0.87–1.17) | |
| Adjusted DM | |||||
| Men | Yes | 0.93 (0.74–1.16) | 0.92 (0.77–1.10) | 1.15 (0.91–1.45) | 0.99 (0.83–1.18) |
| No | 1.08 (0.85–1.37) | 1.00 (0.68–1.49) | 1.11 (0.83–1.53) | 1.06 (0.90–1.26) | |
| Women | Yes | 0.91 (0.80–1.04) | 0.93 (0.74–1.17) | 1.27 (0.99–1.64) | 0.97 (0.87–1.07) |
| No | 1.18 (0.94–1.49) | 1.13 (0.78–1.65) | 1.03 (0.92–1.16) | 1.11 (0.91–1.34) | |
| Total cohort | Yes | 0.91 (0.83–1.01) | 1.00 (0.94–1.06) | 1.20 (1.12–1.28)* | 0.99 (0.91–1.07) |
| No | 1.11 (0.95–1.30) | 1.02 (0.83–1.25) | 1.05 (0.94–1.17) | 1.06 (0.95–1.18) | |
| Adjusted EI | |||||
| Men | Yes | 0.89 (0.72–1.10) | 0.87 (0.73–1.04) | 1.21 (0.96–1.52) | 0.98 (0.81–1.18) |
| No | 1.12 (0.92–1.36) | 1.10 (0.82–1.48) | 1.08 (0.84–1.40) | 1.10 (0.94–1.29) | |
| Women | Yes | 0.97 (0.84–1.11) | 0.94 (0.75–1.18) | 1.36 (1.05–1.75)* | 1.02 (0.92–1.13) |
| No | 0.97 (0.74–1.27) | 1.11 (0.77–1.60) | 1.02 (0.91–1.14) | 1.00 (0.87–1.15) | |
| Total cohort | Yes | 0.94 (0.84–1.04) | 0.89 (0.78–1.03) | 1.30 (1.14–1.47)* | 1.00 (0.92–1.10) |
| No | 1.00 (0.89–1.14) | 0.99 (0.87–1.13) | 1.09 (0.99–1.21) | 1.03 (0.94–1.13) | |
| Study quality | |||||
| Men | 8 or 9 | 0.97 (0.82–1.14) | 0.90 (0.72–1.13) | 1.09 (0.87–1.37) | 0.98 (0.83–1.16) |
| <8 | 1.20 (0.72–1.99) | 0.96 (0.78–1.18) | 1.22 (0.94–1.58) | 1.17 (1.04–1.32)* | |
| Women | 8 or 9 | 0.96 (0.82–1.13) | 0.99 (0.71–1.39) | 1.48 (1.02–2.13) | 1.01 (0.89–1.15) |
| <8 | 0.98 (0.82–1.18) | 0.98 (0.80–1.20) | 1.04 (0.93–1.16) | 0.99 (0.92–1.06) | |
| Total cohort | 8 or 9 | 0.95 (0.87–1.05) | 1.00 (0.94–1.06) | 1.18 (1.06–1.31)* | 0.99 (0.90–1.09) |
| <8 | 1.01 (0.85–1.19) | 0.95 (0.84–1.08) | 1.14 (0.99–1.30) | 1.04 (0.96–1.13) | |
*BMI body mass index, DM diabetes mellitus, EI energy intake
Fig. 5Funnel plot for the association between alcohol intake and the risk of pancreatic cancer